We apply an entrepreneurial spirit to everything we do. We build long lasting relationships with our clients based on mutual trust. Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele.
Vator Securities is led by experienced professionals who have between 15 to 25 years of capital market and advisory experience from some of the world’s most prominent investment banks. Our service offering includes:
- Pre-IPO Financing
- IPOs and Secondaries
- Capital Markets Advisory
- Strategic Advisory
- Equity Research
Vator Securities distinguishes itself by the firm’s ability to raise capital from traditional institutional investors, as well as from its proprietary global network of family offices and high net worth investors. The unique network of investors implies that Vator Securities can source capital irrespective of financial market sentiments and create liquidity in the stock post IPO.
At Vator Securities every project is more than a single transaction. We specialize in providing partnerships where we work long-term with the client and support the value creation of a company long before a transaction commences. We focus on building a long-term strategy for our clients by guiding and consulting extensively throughout the entire life cycle – from idea to completion, but also through follow-ups and post transaction consulting and support.
Vator Securities completed transactions
Sprint Bioscience
21 MSEK | Directed Share Issue | Q2 2021
Financial Adviser
Epulze
57 MSEK | Private Placement | Q2 2021
Financial Adviser
CombiGene
75 MSEK | Rights Issue | Q1 2021
Financial Adviser
SiB Solutions
23 MSEK | Private Placement | Q4 2020
Financial Adviser
Xintela
37 MSEK | Warrants | Q4 2020
Financial Adviser
NextCell Pharma
150 MSEK | Rights Issue | Q4 2020
Financial Adviser
Scandion Oncology
236 MSEK | Rights Issue | Q4 2020
Financial Adviser
Moberg Pharma
150 MSEK | Rights Issue | Q4 2020
Financial Adviser
SciBase
32 MSEK | Warrants | Q4 2020
Financial Adviser
A3P Biomedical
110 MSEK | Private Placement | Q3 2020
Financial Adviser
Fundler
17 MSEK | Private Placement | Q2 2020
Financial Adviser
Xintela
40,5 MSEK | Rights Issue | Q2 2020
Financial Adviser
LIDDS
59,3 MSEK | Directed & Rights Issue | Q2 2020
Sole Bookrunner
Immunovia
400 MSEK | Directed Share Issue | Q2 2020
Joint Bookrunner
Xbrane Biopharma
146 MSEK | Directed Share Issue | Q2 2020
Global Coordinator and Sole Bookrunner
NextCell Pharma
25 MSEK | Rights Issue | Q2 2020
Financial Adviser
SciBase Holding
25 MSEK | Rights Issue | Q2 2020
Financial Adviser
Plastics Unbound
21,7 MSEK | Private Placement | Q4 2019
Financial Adviser
SenzaGen
106 MSEK | Directed & Rights Issue | Q4 2019
Sole Bookrunner
Nanoform
106 MSEK | Private Placement | Q2 2019
Financial Adviser
Empros Pharma
40 MSEK | Private Placement | Q2 2019
Financial Adviser
Xbrane Biopharma
238 MSEK | Directed & Rights Issue | Q2 2019
Sole Bookrunner
Bio-Works
70 MSEK | Directed & Rights Issue | Q2 2019
Sole Bookrunner
Xbrane Biopharma
59 MSEK | Rights Issue | Q1 2019
Financial Adviser
Ascelia Pharma
200 MSEK | IPO | Q1 2019
Sole Global Coordinator and Bookrunner
AlzeCure
200 MSEK | IPO | Q4 2018
Sole Global Coordinator and Bookrunner
Nanoform
71 MSEK | Private Placement | Q2 2018
Financial Adviser
AlzeCure
40 MSEK | Private Placement | Q2 2018
Financial Adviser
Immunovia
324 MSEK | Direct share issue | Q2 2018
Sole Bookrunner
Plastics Unbound
50 MSEK | Private Placement | Q2 2018
Financial Adviser
Ascelia Pharma
60 MSEK | Private Placement | Q1 2018
Financial Adviser
Bio-Works
80 MSEK | IPO | Q4 2017
Sole Bookrunner
IRRAS
334 MSEK | IPO | Q4 2017
Financial Advisor
SenzaGen
90,1 MSEK | IPO | Q3 2017
Sole Bookrunner
TerraNet
100 MSEK | IPO | Q2 2017
Sole Bookrunner
Bio-Works
30 MSEK | Private Placement | Q2 2017
Financial Adviser
AlzeCure
70 MSEK | Private Placement | Q2 2017
Financial Adviser
Biovica
60 MSEK | IPO | Q1 2017
Sole Bookrunner
Acarix
140,4 MSEK | IPO | Q4 2016
Sole Bookrunner
Immunovia
189,9 MSEK + 28,7 MSEK | Q3 2016
Private Placement & Rights Issue
Sole Bookrunner
Nilar
50 MSEK | Private Placement | Q2 2016
Financial Adviser
Xbrane Biopharma
100 MSEK | IPO Q4 | 2015
Sole Bookrunner
Vikingaliv
113,6 MSEK | Private Placement | Q2 2015
Financial Adviser